Sima Canaan‐Kühl

Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease

Malte Lenders, Leon Paul Neußer, Michael Rudnicki et al. · Journal of the American Society of Nephrology · 2018 · 74 citations

Life Sciences, Clinical Sciences, Pharmacology +15

Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch

Frank Weidemann, Johannes Krämer, Thomas Duning et al. · Journal of the American Society of Nephrology · 2014 · 68 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +13

Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)

Malte Lenders, Peter Nordbeck, Christine Kurschat et al. · Clinical Pharmacology & Therapeutics · 2020 · 68 citations

Life Sciences, Pharmacology, Pharmacotherapy +17

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant

Malte Lenders, Frank Weidemann, Christine Kurschat et al. · Orphanet Journal of Rare Diseases · 2016 · 66 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

Global cardiac alterations detected by speckle-tracking echocardiography in Fabry disease: left ventricular, right ventricular, and left atrial dysfunction are common and linked to worse symptomatic status

Daniel A. Morris, Daniela Blaschke, Sima Canaan‐Kühl et al. · International journal of cardiac imaging · 2014 · 63 citations

Medicine, Cardiology, Clinical Cardiology +10